Moderna, Abivax, Amgen, AbbVie, and Revolution Medicines are the five Biotech stocks to watch today, according to MarketBeat's stock screener tool. Biotech stocks are shares of publicly traded companies that develop or sell biotechnology products, such as medicines, vaccines, and diagnostic tools. For investors, they can offer significant growth potential but often carry higher risk and volatility because a company’s prospects may depend on clinical-trial results, regulatory approval, and continued funding. These companies had the highest dollar trading volume of any Biotech stocks within the last several days.
Moderna (MRNA)
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.
Shares of Moderna stock traded down $0.12 on Friday, reaching $199.21. The stock had a trading volume of 4,185,189 shares, compared to its average volume of 12,446,662. The company has a quick ratio of 3.47, a current ratio of 3.62 and a debt-to-equity ratio of 0.52. The stock has a market capitalization of $80.61 billion, a P/E ratio of -28.14 and a beta of 1.16. The company has a 50 day moving average price of $206.87 and a 200 day moving average price of $99.61. Moderna has a 1 year low of $22.28 and a 1 year high of $280.80.
Read Our Latest Research Report on MRNA
Abivax (ABVX)
ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.
Shares of ABVX traded down $8.78 during midday trading on Friday, hitting $71.87. 10,270,961 shares of the company's stock traded hands, compared to its average volume of 1,408,884. The stock has a market capitalization of $6.29 billion, a price-to-earnings ratio of -11.70 and a beta of 1.36. The firm's fifty day moving average is $92.07 and its 200-day moving average is $111.93. Abivax has a 1 year low of $62.70 and a 1 year high of $148.83.
Read Our Latest Research Report on ABVX
Amgen (AMGN)
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.
NASDAQ:AMGN traded up $1.04 during trading hours on Friday, hitting $439.86. 1,264,272 shares of the company were exchanged, compared to its average volume of 2,735,542. The company has a debt-to-equity ratio of 3.60, a current ratio of 1.48 and a quick ratio of 1.20. Amgen has a 52-week low of $312.39 and a 52-week high of $483.99. The stock has a market capitalization of $237.92 billion, a price-to-earnings ratio of 25.48, a PEG ratio of 3.09 and a beta of 0.43. The company's 50 day moving average price is $429.28 and its 200-day moving average price is $383.32.
Read Our Latest Research Report on AMGN
AbbVie (ABBV)
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.
AbbVie stock traded up $5.05 during mid-day trading on Friday, hitting $288.59. The company had a trading volume of 1,793,108 shares, compared to its average volume of 6,251,343. The company has a market capitalization of $510.12 billion, a price-to-earnings ratio of 49.69, a P/E/G ratio of 1.30 and a beta of 0.20. AbbVie has a 12-month low of $190.75 and a 12-month high of $302.93. The company's fifty day moving average is $278.40 and its 200-day moving average is $242.25.
Read Our Latest Research Report on ABBV
Revolution Medicines (RVMD)
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies.
RVMD traded up $2.33 during midday trading on Friday, hitting $161.76. 2,112,555 shares of the company traded hands, compared to its average volume of 2,808,561. The company has a market capitalization of $34.99 billion, a price-to-earnings ratio of -17.83 and a beta of 1.44. The business has a 50 day simple moving average of $190.87 and a two-hundred day simple moving average of $160.71. Revolution Medicines has a 52-week low of $69.50 and a 52-week high of $224.31. The company has a current ratio of 8.36, a quick ratio of 8.34 and a debt-to-equity ratio of 0.44.
Read Our Latest Research Report on RVMD
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Moderna, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Moderna wasn't on the list.
While Moderna currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Oil still powers the global economy, but AI is reshaping the energy opportunity. Discover seven stocks spanning traditional energy, infrastructure, and next-generation power.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.